Indices Update: Nifty Pharma Index Up 0.25% in Global Market Surge

Sunday, 15 September 2024, 22:50

Indices updates reveal that the Nifty Pharma index has advanced 0.25% in an upbeat market. Key players driving this growth include Biocon Ltd. and Sanofi India Ltd. The overall stock market indices are showing positive momentum, reflecting robust trading activity.
Indiatimes
Indices Update: Nifty Pharma Index Up 0.25% in Global Market Surge

NEW DELHI: The Nifty Pharma index traded positive around 11:20AM(IST) on Monday in an upbeat market. Biocon Ltd. (up 3.48 per cent), Sanofi India Ltd. (up 1.07 per cent), Torrent Pharmaceuticals Ltd. (up 0.85 per cent), Aurobindo Pharma Ltd. (up 0.63 per cent), and Sun Pharmaceutical Industries Ltd. (up 0.57 per cent) were among the top gainers. In contrast, Mankind Pharma Ltd. (down 1.91 per cent), Natco Pharma Ltd. (down 0.97 per cent), J B Chemicals & Pharmaceuticals Ltd. (down 0.86 per cent), Laurus Labs Ltd. (down 0.81 per cent), and Abbott India Ltd. (down 0.54 per cent) were the top losers on the index.

The Nifty Pharma index was up 0.25 per cent at 23515.7 at the time of writing this report. The benchmark NSE Nifty50 index was up 28.8 points at 25385.3, while the BSE Sensex was up 76.32 points at 82967.26.

Among the 50 stocks in the Nifty index, 28 were trading in the green, while 22 were in the red. Shares of Bajaj Housing Fin, Vodafone Idea, YES Bank, Suzlon Energy, and Zomato were among the most traded shares on the NSE. Furthermore, shares of Oswal Green Tech, Biofil Chem, Nintec Systems Ltd., EPACK Durables, and Sundaram-Clayton hit their fresh 52-week highs in today's trade, while Future Market, Antarctica Ltd, Viji Finance, Oriental Trimex, and Sumit Woods hit fresh 52-week lows in trade.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe